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Background: Complex clinical interventions are increasingly subject to evaluation by randomised trial linked to
economic evaluation. However evaluations of policy initiatives tend to eschew experimental designs in favour of
interpretative perspectives which rarely allow the economic evaluation methods used in clinical trials. As evidence
of the cost effectiveness of such initiatives is critical in informing policy, it is important to explore whether
conventional economic evaluation methods apply to experimental evaluations of policy initiatives.
Methods: We used mixed methods based on a quasi-experimental design to evaluate a policy initiative whose aim
was to expedite the modernisation of gastroenterology endoscopy services in England. We compared 10 sites
which had received funding and support to modernise their endoscopy services with 10 controls. We collected data
from five waves of patients undergoing endoscopy. The economic component of the study compared sites by
levels of investment in modernisation and patients’ use of health service resources, time off work and health related
quality of life.
Results: We found no statistically significant difference between intervention and control sites in investment in
modernisation or any patient outcome including health.
Conclusions: This study highlights difficulties in applying the rigour of a randomised trial and associated technique
of economic evaluation to a policy initiative. It nevertheless demonstrates the feasibility of using this approach
although further work is needed to demonstrate its generalisability in other applications. The present application
shows that the small incentives offered to intervention sites did not enhance modernisation of gastroenterology
endoscopy services or improve patient outcomes.
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Clinical interventions are increasingly evaluated by
randomised controlled trials (RCTs). The methods of
economic evaluation which are used alongside RCTs are
becoming well established e.g. [1,2]. In contrast evalua-
tors of policy initiatives tend to eschew experimental
designs, advocating more interpretative perspectives [3]
and adopting context-dependent approaches like ‘realistic* Correspondence: david.cohen@southwales.ac.uk
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reproduction in any medium, provided the orevaluation’ [4]. These are less amenable to the rigorous
economic evaluation methods used in clinical trials.
In recent years, however, there have been efforts to ex-
tend the rigour of the RCT to the evaluation of clinical in-
terventions that are more complex than single treatments.
For example, the UK Medical Research Council (MRC)
has developed a framework for the design and evaluation
of ‘complex interventions’ which includes a definitive
RCT [5]. Policy initiatives are arguably even more com-
plex than complex clinical interventions. Given the need
for evidence of the effectiveness of policy initiatives, how-
ever, the rigour of the RCT is still the goal. This paper
describes a study which evaluated a policy initiative using
a quasi-experimental approach and economic appraisal.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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In 2002, the National Health Service Modernisation
Agency (NHSMA) initiated its Modernising Endoscopy
Services (MES) programme to help gastroenterology
departments in England modernise their endoscopy ser-
vices. The specific purpose of the MES programme was
to improve waiting times and throughput of endoscopy
services by better matching demand and supply in en-
doscopy units and thus improve clinical outcomes. Fol-
lowing a pilot study, NHSMA chose 26 sites to receive
£30,000 to fund approved service redesign plans and
provided them with specially designed data software
(Toolkit™) to analyse their endoscopy services, together
with training and support from the MES itself. The
Toolkit™ required the daily input of the number of refer-
rals, patients waiting and lost appointment slots by pro-
cedure type and reason. These data were used by the
endoscopy staff to monitor services and were uploaded
to the MES programme for external analysis. Sites whose
applications were unsuccessful were still eligible to use
the Toolkit™ outside the MES programme.
This paper describes the methods and results of apply-
ing standard economic appraisal principles to evaluate
the MES project. The final section discusses how the
economic evaluation of this policy initiative differed
from that in traditional clinical trials.
Methods
The National Institute for Health Research funded the
ENIGMA study (‘Evaluating New approaches In Gas-
troenterology initiated by the Modernisation Agency)
through its Service Delivery and Organisation Programme
to conduct an independent evaluation of the impact of the
MES programme on services, patients and professionals
[6]. ENIGMA adopted a quasi-experimental approach by
selecting and recruiting random samples of ten of the 26
‘intervention’ sites chosen by the NHSMA and ten of the
70 ‘control’ sites whose applications for funding to support
modernisation had been unsuccessful; we stratified both
samples by number of beds in the hospital.
We collected data from patients referred to these sites
for endoscopy across five waves from April 2004 to April
2006. We assessed 9,154 patients for eligibility and in-
vited 7,974 to participate; 3,818 consented to take part.
ENIGMA gained ethical approval from the Wales Multi-
Centre Research Ethics Committee and research govern-
ance approval from each site.
The controlled nature of ENIGMA made it a good
candidate for economic evaluation. It addressed five
economic questions:
1. What was the cost of modernisation in each site?
2. Did modernisation costs differ between intervention
and control sites?3. Was there a difference in use of other NHS
resources between intervention site patients and
control site patients?
4. Was there a difference in time off work between
intervention and control site patients?
5. Was there a difference in health outcomes as
measured by quality adjusted life-years (QALYs)
between intervention and control site patients?
These are standard economic evaluation questions to
address rigorously when undertaking economic evalu-
ation alongside clinical trials. Attempting to apply them
to a policy initiative, however, created numerous difficul-
ties which often required creativity to overcome.
Economic methods
The main economic analysis was a cost-utility study com-
paring total NHS costs with effects in terms of QALYs.
Cost of modernisation
In economic evaluation alongside clinical trials, estima-
tion of direct intervention costs, i.e. the value of the
resources used in the provision of the intervention, is
normally straightforward in well-defined interventions.
Although the MES project sought to modernise endos-
copy services, we could not find a widely agreed defin-
ition of ‘modernisation’, on which the cost of the
intervention depends. As the stated challenge of the final
phase of the MES project was to “introduce new ways of
working”, for purposes of ENIGMA we defined modern-
isation as changes in working practices. Examples of such
modernisation thus included changing methods (e.g. new
IT systems to manage waiting lists), altering staff skill mix
(e.g. training nurses to perform endoscopy), purchasing
different equipment (e.g. long term decontamination
units) and setting up new processes to monitor progress
(e.g. modernisation team meetings). However we did not
consider doing more of the same, for example by increas-
ing staff numbers, as modernisation, although this clearly
represents service improvement.
As many modernising changes began before the start
of the evaluation we could not specify costs at the level
of precision normally possible in prospective monitoring
of resource use in economic evaluations alongside clin-
ical trials. Instead, we estimated the resource costs of
modernisation via two rounds of semi-structured inter-
views with key personnel at each study site, completed
one year apart, early in 2006 and 2007. We asked sites
to identify the individual with most knowledge of all as-
pects of the endoscopy service at that site to act as our
informant. In response they nominated a range of man-
agerial (e.g. Endoscopy Manager, Clinical Services Man-
ager) and clinical (e.g. Consultant, Nurse Consultant,
Endoscopy Sister) staff.
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vide relevant documentary sources describing its mod-
ernisation efforts and related resource consequences.
We reviewed these and sent summaries to the selected
informants before their first interview. These began with
an explanation of principles to ensure that respondents
had a clear understanding of what we considered a cost
of modernisation. The second interview gave them the
opportunity to respond to queries from the first inter-
view and identify developments since the first visit.
Following standard methods of economic evaluation,
we then measured resources which had been identified
as contributing to modernisation in relevant natural or
physical units and valued them using local data or
national sources. In particular we valued staff hours
according to grade; where we could not be sure of the
grade, we estimated costs from the mid-point of the
scale for similar advertised jobs [7].
Costs of off-site training courses undertaken by staff
explicitly for modernisation included the money paid for
courses where known, or else the cost for similar courses
from web sources [8], plus the value of the trainee's
time. In-house training included time of trainer and
trainee, again valued according to grade. Where training
led to staff re-grading, we included the extra cost of the
re-graded post in the costs of modernisation.
We used the equipment costs incurred by sites, or else
the most frequently incurred cost for similar equipment
by other sites. We considered both training and equip-
ment as one-off investments providing a flow of benefits
over time and amortised all such costs by assuming five-
year lifetimes and using a universal discount rate of 3.5%
[9]. We also undertook a sensitivity analysis to test the
effect of 10-year lifetimes on the costs of training and
equipment. We adjusted all costs to common 2006
prices using the Health Service Price Index.
Patients’ use of other health service resources
Modernising endoscopy services may also have indirect
consequences for other health service resources. For
example, shorter waiting times could affect patients’ use
of General Practitioner (GP) services. We therefore col-
lected data on patients’ use of other NHS services by
questionnaires to patients recruited in five waves begin-
ning in April 2004 and ending in April 2006. Each wave
completed questionnaire at referral (Baseline Question-
naire – BQ), immediately after the procedure (Post
Procedure Questionnaire – PPQ) and twelve months
thereafter (12MQ). The time between being referred and
undergoing the procedure varied between patients. We
accepted returned questionnaires until the end of 2007.
Where data were missing for the 12MQ, the last case
carried forward method was adopted. For example
where BQ (time point 0) and PPQ (time point 1) datawere present but 12MQ (time point 2) data were miss-
ing, data were carried forward from the PPQ. A further
weighting of the carried forward PPQ, based on the rela-
tive relationship of PPQ to 12MQ data, was not adopted
as it was anticipated to be unlikely to have any major
impact on the results.
When we undertook ENIGMA, there was little guid-
ance how to collect resource use by patient recall, e.g.
[10]. We therefore adapted a patient recall questionnaire
which we had previously used successfully [11]. Questions
asked patients about visits to GP surgeries and outpatient
clinics, home visits by health professionals, hospital ad-
missions including as a day case, and drugs prescribed –
all within the three-month period before completing each
questionnaire. Although use of a 3 month period produces
gaps in the data, it has the advantage of providing more
accurate patient recall of resource use than over longer
periods [12]. Accuracy was considered more important
than completeness as the focus here is on differences
between groups. Table 1 shows the unit costs of these
resources. Given the short timescale, we did not discount
these costs.
Value of patients’ lost productivity
Economic appraisals need to specify the perspective of
their evaluations. In the UK, the National Institute for
Health and Care Excellence (NICE) guides the cost-
effective use of the National Health Service (NHS)
budget by recommending which treatments the NHS
should provide. It therefore prefers the perspective of
NHS and personal social services [1].
Although there are also theoretical arguments to
support this narrower perspective [18] we additionally
assessed time off work by service uses as this might be
reduced by improved service delivery. This was done by
asking questions about time lost from work in BQ, PPQ
and 12MQ. We compared lost work time and its value,
estimated using average male and female earnings from
Table 1.
Quality of life and statistical analysis
For economic evaluation, our primary outcome was
health-related quality of life measured by the EQ-5D
[19], which are then converted into QALYs. We under-
took analysis of covariance (ANCOVA) with QALY
scores as dependent variable, group (intervention or
control) as primary independent variable, and age, gen-
der, procedure type, degree of urgency, waiting time (i.e.
time between BQ and PPQ), NHS resource use before
baseline, number of beds and teaching status of hospital,
wave of recruitment and innovation scores as covariates.
Recruiting a large sample across many sites or ‘clus-
ters’ carries a risk of losing statistical power through
intra-site correlation. We therefore augmented analysis
Table 1 Unit costs and sources
Data item £ unit cost Source
GP (surgery visit) £21 [13]
Nurse (surgery visit) £8 [13]
GP (home visit) £60 [13]
Nurse (home visit) £11 [13]
Social services/Social worker £60 [13]





Physiotherapist session £36 [14]
Paramedics/Ambulance £161 [14]
Chiropodist/Podiatrist £31 [14]
Occupational therapist £36 [14]
Chiropodist/Podiatrist £31 [14]
Colonoscopy £352 [14]
Flexible sigmoidoscopy £279 [14]
Gastroscopy £275 [14]
Day case endoscopy £457 [14]
Endoscopy slot £2727 [14]*
Inpatient per day: medical £269 [15] (inflated)
Outpatient episode £96 [15] (inflated)
Avg. weekly earnings male £105 [16]
Avg. weekly earnings female £81.20 [16]
Drugs Priced individually from [17]
*Slot = 12 points. Cost of slot based on assumed ½ session for colonoscopy
(2 points) and ½ session for sigmoidoscopy/gastroscopy (1 point) per procedure.
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this issue, in particular in costs at PPQ and 12MQ, using
MLWin version 2.0 [21].
As PPQ and 12MQ questionnaires varied in the length
of waiting time from baseline, an ANCOVA based ad-
justment was carried out on data from these two ques-
tionnaires to account for baseline effects across all
resource use items as well as for costs. To address theTable 2 Mean (SD) costs, activity and marginal costs


































P values (95% CI) for totals.inevitable skewness in cost data, we also used non-
parametric bootstrapping [22] when analysing costs.Results
Cost of modernisation
Table 2 shows the estimated mean costs of modernisa-
tion. As it proved difficult to specify exactly when many
modernisation activities began, we treated all training
and equipment costs that occurred during the 12-month
modernisation period between site visits as ‘initial’ costs
occurring simultaneously. We adopted the same ap-
proach to ‘one-off ’ costs of other activities which fin-
ished when modernisation was complete.
Table 2 shows total initial costs in column 7. This is
the sum of the Equivalent Annual Cost (EAC) of equip-
ment and training (column 4), the one-off costs (column
5) and the annual recurring costs such as permanent
new modernisation-related posts (column 6). Dividing
these initial costs by the activity (i.e. average number of
endoscopies) in 2004 yields the marginal initial cost per
patient i.e. the additional cost per patient due to mod-
ernisation. Table 2 also shows costs in subsequent years,
namely recurring costs plus EAC of training and equip-
ment, the activity in 2005 and the resulting marginal
subsequent cost per patient-year.
All costs varied widely: equipment from zero to
£260,000; training from £400 to £31,000; and in one-off
costs from zero to £245,000. As an example of the latter,
one site produced a ‘modernisation initiative endoscopy
list’ and cleared it by sending patients to the local private
hospital (£68,000).
The mean total initial cost was £131,000 (SD = £82,000)
for intervention sites and £134,000 (SD = £101,000) for
control sites. The difference of £3,000 in favour of the
intervention was not statistically significant (95% CI from
-£88,745 to £94,783). The mean total cost for subsequent
years was £79,000 (SD = £72,000) in intervention sites and
£93,000 (SD = £95,000) in control sites. The difference of
£14,000 in favour of the intervention was also not signifi-
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in marginal costs per patient between intervention and
control sites either in initial or in subsequent years.
The mean difference in initial marginal costs was £7
in favour of the intervention (95% CI from -£14 to
£28) and the difference in marginal costs for subse-
quent years was £3 in favour of the invention (95% CI
from -£14 to £21). The sensitivity analysis assuming a
10-year lifetime for training and equipment did not
change the relative costs of intervention and control
sites and the differences remained not statistically
significant.
Patients’ use of other health service resources
After the first wave of patient recruitment, one interven-
tion and one control site were withdrawn from the study
because they were unable to comply with the strict
patient recruitment criteria [6]. Patient-level data on use
of NHS resources, time off work and quality of life were
thus available for 18 of the 20 recruited sites (9 interven-
tion, 9 control). A total of 3,818 BQs, 2,940 PPQs andTable 3 Mean cost (standard error) of other NHS resources
Total primary c







W1 £68.59 (4.28) £75.37 (5.03) 0.31 £61.81 (4.75)
W2 £79.71 (6.67) £74.32 (4.11) 0.49 £70.70 (5.76)
W3 £72.48 (4.96) £69.25 (3.72) 0.6 £50.41 (3.64)
W4 £65.02 (3.83) £84.13 (8.74) 0.04 £52.30 (3.25)
W5 £69.95 (4.58) £77.19 (6.17) 0.34 £53.15 (3.72)
Total secondary
W1 £262.78 (24.20) £311.05 (25.17) 0.17 £691.44 (27.25) £
W2 £292.48 (25.91) £336.44 (34.21) 0.31 £718.58 (34.03) £
W3 £263.71 (24.26) £300.95 (31.32) 0.36 £626.22 (32.71) £
W4 £257.34 (20.92) £301.73 (24.41) 0.17 £681.62 (29.51) £
W5 £302.09 (27.55) £275.88 (23.89) 0.48 £653.91 (25.11) £
Total cost of m
W1 £33.36 (3.13) £35.81 (3.82) 0.62 £33.29 (2.99)
W2 £27.03 (2.55) £43.82 (4.01) 0.00 £29.07 (3.01)
W3 £33.31 (3.15) £40.17 (3.00) 0.12 £33.60 (3.03)
W4 £36.36 (3.45) £38.40 (3.13) 0.66 £36.23 (3.54)
W5 £40.09 (3.78) £42.32 (3.43) 0.66 £40.62 (4.26)
Total NH
W1 £364.72 (25.37) £422.24 (26.77) 0.13 £786.55 (29.11) £
W2 £399.22 (27.96) £454.58 (35.44) 0.22 £818.35 (35.81) £
W3 £369.52 (26.58) £410.38 (32.28) 0.34 £715.01 (34.55) £
W4 £358.72 (22.04) £424.26 (27.07) 0.07 £770.15 (30.58) £
W5 £412.12 (28.86) £395.39 (25.78) 0.67 £747.68 (26.67) £
BOLD: p ≤ .05.2,588 12MQs were available for complete case analyses
(CCA). Imputation of missing data increased the num-
ber of analysable PPQs to 3055 and 12MQs to 3039.
However, comparison of mean differences between pa-
tients in intervention and control sites showed little
difference in results between methods. For example, all
differences that were statistically significant (p <0.05) in
the CCA remained significant with imputation and no
non-significant results became significant. Thus al-
though the imputation used the full dataset, it had little
effect on results. It was therefore decided to report
results only from the CCA.
Results of the multi-level modelling (MLM) did not
show any statistically significant effects between sites on
the five selected cost variables in either PPQ or 12MQ. Es-
timates of intra-site correlation, which reflect the degree
of clustering at site-level, did not show any statistically
significant site effects for the observed resource use data.
Accordingly we conducted no further MLM analyses and
report the remaining results without the minimal adjust-
ments for clustering.are cost (£)








£60.51 (3.80) 0.83 £45.51 (3.89) £52.03 (4.03) 0.25
£68.61 (4.41) 0.77 £56.18 (5.69) £57.00 (5.63) 0.92
£72.41 (5.12) 0.00 £43.07 (4.75) £52.43 (7.71) 0.32
£63.67 (5.22) 0.06 £49.87 (4.51) £52.84 (5.44) 0.67
£59.53 (3.79) 0.23 £37.15 (3.16) £71.46 (17.77) 0.06
care cost (£)
714.36 (31.44) 0.59 £227.74 (30.31) £181.84 (21.34) 0.21
694.83 (33.67) 0.62 £187.67 (24.52) £257.31 (44.29) 0.18
717.11 (30.52) 0.04 £151.09 (22.15) £222.11 (31.16) 0.07
698.94 (34.42) 0.70 £174.83 (27.07) £265.52 (56.68) 0.15
625.13 (25.92) 0.43 £162.94 (23.92) £207.48 (30.28) 0.25
edication (£)
£44.80 (4.98) 0.05 £31.12 (3.32) £43.05 (4.82) 0.05
£40.00 (3.28) 0.02 £30.89 (3.25) £42.18 (5.57) 0.02
£42.92 (3.78) 0.06 £33.02 (3.55) £45.87 (5.00) 0.04
£42.05 (4.33) 0.29 £36.25 (3.81) £48.37 (4.70) 0.05
£41.66 (3.67) 0.86 £39.29 (5.73) £46.65 (5.67) 0.36
S cost
819.66 (33.98) 0.46 £304.37 (31.42) £276.92 (24.03) 0.48
806.05 (35.42) 0.81 £274.74 (26.13) £356.49 (47.97) 0.14
835.02 (33.17) 0.01 £227.17 (24.09) £320.42 (34.45) 0.03
807.54 (36.32) 0.43 £260.95 (30.26) £366.72 (58.19) 0.10
726.31 (27.70) 0.58 £239.38 (26.24) £325.59 (40.24) 0.07
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split by wave and group. Table 4 shows mean differences
in NHS costs, where baseline costs are bootstrapped and
post procedure and end of follow up costs are adjusted
for baseline differences and waiting time. Most differ-
ences were negative indicating that patients from inter-
vention sites incurred lower costs but few differences
reached statistical significance. All differences which were
statistically significant at PPQ became non-significant at
12MQ. The only statistically significant difference at
12MQ was for drugs in Wave 4 (p = 0.04) but this was not
seen in Wave 5.
Value of patients’ lost productivity
Table 5 shows mean number of days off work and value
of lost productivity by wave. There was a statistically
significant difference in time off work in favour of the
intervention in wave 4 (adjusted mean difference =
-1.78 days; 95% CI from -3.47 to -0.09 days) but not in
any other wave. When valued using relevant averageTable 4 Comparison of bootstrapped mean difference (MD) in
and end of follow up costs by wave: intervention v control
Wave Baseline (n = 3818) Post pr
Bootstrapped
MD (I – C)
p 95% CI Adjusted
MD (I – C)
Primary care cost (£)
W1 -£6.74 0.15 -19.80 to 6.00 £5.15
W2 £5.35 0.75 -7.19 to 24.40 -£2.47
W3 £3.34 0.71 -7.90 to 16.11 -£21.6
W4 -£19.30 0.02 -43.80 to -4.22 -£9.16
W5 -£7.28 0.17 -25.20 to 5.90 -£1.42
Secondary care cost (£)
W1 -£48.30 0.08 -111.30 to 23.80 -£12.50
W2 -£43.40 0.16 -122.50 to 48.40 £23.00
W3 -£37.60 0.17 -116.80 to 37.40 -£66.60
W4 -£44.30 0.08 -107.10 to 17.60 -£7.98
W5 £26.20 0.76 -45.80 to 98.70 £32.70
Drug cost (£)
W1 -£2.46 0.31 -12.30 to 6.90 -£9.99
W2 -£16.90 0.06 -26.50 to -8.20 -£3.90
W3 -£6.90 0.33 -15.40 to 1.40 -£6.10
W4 -£2.05 0.33 -10.50 to 7.60 -£5.00
W5 -£2.23 -11.80 to 8.10 -£2.50
Total NHS cost (£)
W1 -£57.50 0.06 -128.20 to 19.80 -£17.20
W2 -£54.90 0.12 -137.30 to 5.90 £15.50
W3 -£41.10 0.16 -123.90 to 37.90 -£86.90
W4 -£65.60 0.03 -135.08 to -3.10 -£21.20
W5 £16.70 0.66 62.10 to 93.70 £27.20
BOLD: p ≤ .05.earnings (male or female), however, the adjusted mean dif-
ference of -£27 was not statistically significant (95% CI
from -£57 to £3). This result mirrors those seen for other
NHS resources.
Taken together, the results suggest that total costs may
have been lower in intervention sites, but the difference
was not statistically significant.Quality of life
Table 6 shows two statistically significant adjusted mean
differences in QALYs: against the intervention in Wave
2 at 12 months; and favouring the intervention in Wave
5 immediately after the procedure. The differences in
the other 8 analyses were not significant with five
favouring the intervention group and three favouring the
control group. The other quality of life measures used in
ENIGMA replicated this finding that the MES initiative
did not have a statistically significant impact on quality
of life [6].baseline and adjusted mean difference in post procedure
ocedure (n = 2940) End of follow up (n = 2588)
p 95% CI Adjusted
MD (I – C)
p 95% CI
0.33 -5.28 to 15.58 -£5.97 0.28 -16.72 to 4.79
0.69 -15.92 to 9.99 -£1.28 0.87 -16.80 to 14.20
0.00 -32.50 to -10.80 -£8.88 0.34 -27.10 to 9.31
0.11 -20.23 to 1.92 £0.87 0.90 -12.50 to 14.30
0.76 -10.65 to 7.82 -£35.6 0.06 -71.90 to 0.08
0.76 -91.70 to 66.60 £37.60 0.29 -33.40 to 108.60
0.62 -66.70 to 112.70 -£62.60 0.19 -156.20 to 30.90
0.10 -146.20 to 12.09 -£62.90 0.10 -138.60 to 12.60
0.85 -89.10 to 73.20 -£58.60 0.33 -176.00 to 58.90
0.34 -34.90 to 100.40 -£48.60 0.22 -125.90 to 28.60
0.08 -21.01 to 1.10 -£10.60 0.06 -21.80 to 0.54
0.32 -11.70 to 3.80 -£5.90 0.20 -15.00 to 3.10
0.13 -14.10 to 1.80 £8.50 0.15 -19.90 to 2.90
0.24 -13.40 to 3.30 -£10.80 0.04 -2110 to -0.50
0.54 -10.0 to 5.50 -£6.40 0.40 -21.40 to 8.50
0.69 -101.60 to 67.30 £20.60 0.59 -54.70 to 95.80
0.74 -77.00 to 108.00 -£66.00 0.19 -166.60 to 34.60
0.04 -169.80 to -4.10 -£80.10 0.06 -162.50 to 0.30
0.62 -105.60 to 63.30 -£64.00 0.30 -186.30 to 8.30
0.45 -43.80 to 98.00 -£91.40 0.06 -187.30 to 4.50
Table 5 Time off work and value of lost productivity by wave: intervention v control
Baseline (n = 3818) Post procedure (n = 2940) 12 month post procedure (n = 2588)
M.D. (I – C) p 95% CI Adj. M.D. (I - C) p 95% CI Adj. M.D. (I - C) p 95% CI
(D7) Time off from work
W1 -0.03 0.97 -1.55 to 1.49 0.27 0.61 -0.75 to 1.28 -0.48 0.57 -2.12 to 1.16
W2 -1.20 0.22 -3.11 to 0.71 0.49 0.56 -1.16 to 2.13 0.11 0.80 -0.70 to 0.91
W3 0.55 0.37 -0.64 to 1.74 -0.55 0.22 -141 to 0.32 -0.05 0.89 -0.85 to 0.75
W4 1.59 0.07 -0.13 to 3.32 -0.04 0.95 -1.26 to 1.18 -1.78 0.04 -3.47 to -0.09
W5 -0.82 0.28 -2.33 to 0.68 -1.04 0.31 -3.04 to 0.97 -0.16 0.82 -1.58 to 1.26
Cost of Time off from work
W1 -£0.86 0.95 -27.50 to 29.20 £5.47 0.59 -14.40 to 25.30 -£9.80 0.57 -43.40 to 23.90
W2 -18.60 0.28 -52.60 to 15.30 £14.05 0.37 -16.90 to 45.00 £2.40 0.73 -11.60 to 16.50
W3 £12.30 0.29 -10.70-to 35.30 -£10.70 0.15 -25.40 to– 3.90 -£1.45 0.83 -14.80 to 11.90
W4 £32.00 0.05 -0.30 to 64.30 £1.60 0.88 -20.60 to 23.90 -£27.00 0.07 -56.70 to 2.60
W5 -£17.30 0.22 -44.90 to 10.20 -£20.70 0.29 -59.70 to 18.30 -£6.20 0.65 -33.20 to 20.70
BOLD: p ≤ .05.
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The economic questions addressed here were part of a
larger study which examined the impact of the Moder-
nising Endoscopy Services (MES) programme on a range
of criteria by a variety of methods. These included: ques-
tionnaires to study sites about process data and innovation
histories; questionnaires to patients about outcomes and
waiting times; questionnaires to general practitioners with
patients in ENIGMA about the modernisation of endos-
copy services at their local study site; interviews to obtain
the views of patients and professionals working at study
sites; and focus groups to obtain the views of professionals
working at non-study sites. Results from all methods were
essentially consistent with no conflicting messages [6].
The quasi-experimental design of ENIGMA sought to
evaluate whether a policy initiative based on a small fi-
nancial contribution plus non-financial support from
MES programme staff enhanced the modernisation of
endoscopy services. We have previously succeeded in
randomising Primary Care Trusts to evaluate a policy
initiative to facilitate collaboration between general med-
ical practices and community pharmacies in North andTable 6 Adjusted mean difference in QALY scores: PPQ (*) an
PPQ
Adjusted mean difference (I – C) P value (95% CI)
W1 -0.006 0.48 (-.0210 to .010)
W2 0.003 0.74 (-.014 to .020)
W3 0.015 0.08 (-.002 to .031)
W4 0.003 0.75 (-.014 to .019)
W5 0.017 0.04 (.001 to .032)
(*) = post procedure questionnaire.
(**) = 12 month post procedure questionnaire.
BOLD: p ≤ .05.East Yorkshire [23,24]. Not surprisingly, however, the
NHSMA preferred to choose 26 of the 80 applicant sites
which they judged most likely to succeed. Hence the
closest we could come to a rigorous quasi-experiment
was by drawing stratified random samples from these 26
successful sites and the remaining 70 unsuccessful sites.
If the choices made by NHSMA had been better than
random, our evaluation would have been biased.
We also had to compromise when applying standard
economic evaluation methods alongside our quasi-
experiment. While the intervention took the clear form of
support from MES, its aim was to expedite ‘modernisa-
tion’, for which there was no clear definition. Identifying
which investments to include as costs of modernisation
thus required an operational definition. So we chose to de-
fine modernisation as doing things differently rather than
doing more of the same. We then relied on key personnel
to decide whether each activity fitted that definition. Inter-
viewees often had difficulty in accepting that this defin-
ition excluded some initiatives of which they were proud,
for example creating new consultant and nursing posts
which had reduced waiting times. However not alld 12MQ (**)
12mPPQ
Adjusted mean difference (I – C) P value (95% CI)
-0.007 0.15 (-.017 to .003)
-0.012 0.04 (-.023 to -.001)
0.010 0.08 (-.001 to .021)
0.001 0.92 (-.001 to .011)
0.004 0.40 (-.006 to .015)
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mants’ judgment whether an initiative represented mod-
ernisation or improvement was unavoidable and open to
bias. It also proved difficult to isolate investments sup-
ported by the £30,000 provided to intervention sites from
the other investments in modernisation.
Timing also posed several problems. Clinical trials
normally introduce interventions at a defined time,
whereas many study sites had started modernising long
before MES began. This made it difficult to judge
whether the cost of each modernisation activity fell
within the relevant timeframe. Thus the wide variation
in the equipment costs associated with modernisation,
from zero to £260,000, depended on the situation at the
start of the modernisation period. For example, one en-
doscopy service which reported no new equipment costs
had recently occupied a new unit at a cost of some £2.5
million. Nevertheless, since its new equipment was in
place before MES began, we could not attribute the
costs of this equipment to MES. At the other extreme,
one financially constrained service made no investments
in new equipment. Similarly, the wide variation in train-
ing costs, from £444 to £31,100, reflected training needs
at the start of the modernisation period.
The fact that the Department of Health launched MES
at a time when modernisation was one of their key pol-
icy objectives for the NHS as a whole exacerbated these
problems. Thus, despite our use of control sites to adjust
for extraneous factors, the momentum of modernisation
meant that the specific effects of an endoscopy-specific
initiative were sure to be small. In addition, the policy
context did not allow the study design to minimise
contamination between groups as could have been done
within an RCT. Control sites were not barred from using
the Toolkit™ and while we do not know how many did
so, any such use would dilute the intervention effect.
As a major aim of the study was to investigate whether
standard methods of economic evaluation could be ap-
plied to a policy initiative, we intentionally applied a
rigorous costing methodology. While the difficulties dis-
cussed above reduced the precision of our cost esti-
mates, ENIGMA showed that many standard methods
of economic evaluation could be applied without diffi-
culty – in particular to the estimation of the cost of pa-
tients’ use of other health services and the value of
patient level lost productivity and health related quality
of life.
Conclusions
This case study has shown that even for an initiative as
unspecified as Modernising Endoscopy Services, it is
possible to design an economic evaluation alongside a
quasi-experiment, albeit with caveats about the conclu-
sions drawn. This design enabled us to compare theeffects of the MES programme with those of a plausible
alternative.
Subject to those caveats, ENIGMA has concluded that
small incentives such as those offered to intervention
sites by the NHSMA do not stimulate further invest-
ment. Furthermore they do not affect patient outcomes,
other demands on the NHS or losses to industry from
sickness absence. While less rigorous designs can also
draw such economic conclusions, they suffer from the
weaknesses inherent in studies which do not define a
comparator.
Our use of a case study to explore the broad issue of
whether standard economic evaluation techniques can
be applied to policy initiatives using quasi-experimental
designs inevitably raises questions about the extent to
which the messages are generalisable and further appli-
cations are clearly required.
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